A cell ther­a­py biotech finds a de­liv­ery part­ner; FDA re­moves clin­i­cal hold on Ocu­gen's Covid can­di­date

Umo­ja Bio­phar­ma will pair its so-called VivoVec par­ti­cles with Lu­pa­gen’s Side CAR-T de­liv­ery sys­tem to tar­get cer­tain can­cers, the com­pa­nies said Mon­day.

As part of the deal, Umo­ja’s cell ther­a­pies could be de­liv­ered via an ad­di­tion­al route thanks to Lu­pa­gen’s ex­tra­cor­po­re­al in vi­vo tech. The Dal­las gene ther­a­py com­pa­ny’s tech is ex­pect­ed to pro­vide ef­fi­cien­cy and “high­ly con­trolled vi­ral vec­tor tar­get­ing of T cells,” the com­pa­nies added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.